Gilead Sciences

GILDNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$178.839 B

$144.23 -0.28%

Close of 7 Oct 2026

As of 7 Oct 2026, Gilead Sciences (GILD) has a market capitalization of $178.8B. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

$29.4B

#144 by revenue

Earnings

$8.51B

#56 by earnings

Shares outstanding

1,239,955,155

Latest filing cover page

P/E ratio

21.0

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 160 →

#1AmgenAMGN$217.7B
#2Gilead SciencesGILD$178.8B
#3ModernaMRNA$74.8B
#4Argenx SeARGX$57.8B
#5Revolution MedicinesRVMD$42.8B

What if Gilead Sciences were worth as much as…

Open the what-if tool →

Gold $28.8T

$23,218.13

Per share 161× higher

Bitcoin $1.67T

$1,347.02

Per share 9.34× higher

Nvidia $5.77T

$4,649.91

Per share 32.2× higher

Or at a round number

$500.0B $1.00T $2.00T $5.00T

Where these numbers come from

Share counts and financials for Gilead Sciences are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 8 Oct 2026. Read the methodology.